Charles L Campbell
Affiliation: University of Kentucky
- New treatment options for acute coronary syndromesCharles L Campbell
University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T Wethington Bldg, Lexington, KY 40536 0200, USA
Am J Manag Care 12:S435-43. 2006..This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa...
- Aspirin dose for the prevention of cardiovascular disease: a systematic reviewCharles L Campbell
Gill Heart Institute, University of Kentucky, Lexington, USA
JAMA 297:2018-24. 2007..More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose...
- Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudyCharles L Campbell
Gill Heart Institute, University of Kentucky, 326 Charles T Wethington Building, 900 South Limestone, Lexington, KY 40536 0293, USA
J Thromb Thrombolysis 31:139-45. 2011..3.60, P = 0.09). These data suggest that major bleeding is associated with development of a pro-inflammatory state. If confirmed, this mechanism may in part explain the poor prognosis of patients experiencing an acute hemorrhagic event...
- Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation modelJoseph D Foley
Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and Lexington Veterans Administration Hospital, Lexington, Kentucky, USA
Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012..To determine if salivary biomarkers demonstrate utility for identifying aspects of myocardial necrosis...
- G-protein-coupled receptors as signaling targets for antiplatelet therapySusan S Smyth
Veterans Affairs Medical Center, Department of Medicine, Physiology, and Pharmacology, University of Kentucky, Lexington, KY, USA
Arterioscler Thromb Vasc Biol 29:449-57. 2009..The identification and development of new agents directed against specific platelet signaling pathways may offer an advantage in preventing thrombotic events while minimizing bleeding risk...
- Optimal management of hypertension in patients with ischemic heart diseaseDebabrata Mukherjee
Gill Heart Institute and the Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536 0200, USA
Cardiovasc Hematol Agents Med Chem 7:198-205. 2009....
- Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care?Eric L Wallace
Division of Cardiovascular Medicine, Gill Heart Institute, and the College of Public Health, University of Kentucky, Lexington, KY 40536, USA
South Med J 106:391-8. 2013..Regional approaches have been developed with success and we sought to increase guideline compliance in Kentucky...
- Oral fluids that detect cardiovascular disease biomarkersJoseph D Foley
Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536 0297, USA
Oral Surg Oral Med Oral Pathol Oral Radiol 114:207-14. 2012..The aim of this study was to determine the utility of oral fluids for assessment of coronary and cardiovascular (CV) health...
- Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonistsAlison L Bailey
Gill Heart Institute at University of Kentucky and Lexington Veterans Administration Hospital, Lexington, KY, USA
Curr Drug Targets 12:1805-12. 2011..This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS...
- Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrelJulie H Oestreich
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
Coron Artery Dis 20:207-13. 2009..Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes...
- Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusionsSamy Selim
Division of Cardiovascular Medicine, The Gill Heart Institute, 741 S Limestone Street, Lexington, KY 40536 0509, USA
Clin Sci (Lond) 121:565-72. 2011..Changes in S1P content may contribute to an RBC storage lesion. Further studies should investigate the clinical significance of alterations in circulating S1P levels and the potential value of enriching stored RBCs with S1P...
- Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular diseaseFredric J Pashkow
John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
Am J Cardiol 101:58D-68D. 2008....
- Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snagDavid J Moliterno
J Am Coll Cardiol 49:2318-9. 2007
- Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro studyCharles L Campbell
Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA
Am Heart J 150:796-9. 2005..N-Acetylcysteine (NAC) is able to reduce disulfide bonds. We postulated that NAC might reverse clopidogrel's effect on platelets...